My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

To keep patients at the center of our process, the Max team asked patient leaders and associations from around the world to send in their own questions about TFR. We compiled their submissions, identified common themes, and narrowed the field down to 10 key questions.

Download the My PCR Treatment-Free Remission FAQ (PDF)

The answers in the FAQ were provided by CML expert, Max Medical Advisor, and friend of the organization, Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center. Thanks to his extensive knowledge and experience, the document offers valuable information for patients and providers alike.

This FAQ marks another new resource created by The Max Foundation’s My PCR initiative – a global effort to increase access to polymerase chain reaction (PCR) testing for CML.

The Max Foundation extends its thanks to all the generous sponsors who make the My PCR initiative possible:

  • Major Sponors: Bristol-Myers Squibb, Pfizer, Novartis, and Takeda Oncology
  • Supporting Sponsors: Asuragen, Cepheid, and Incyte

With their support we’re expanding access to critical diagnostics in low- and middle-income countries around the world.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.

  • First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….

  • The Max Foundation’s 2019 Annual Report is Now Live

    The Max Foundation’s 2019 Annual Report is Now Live

    “Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.